GS-0938 | PSI-352938 | PSI-938 | CAS#1231747-17-3 | HCV NS5B inhibitor

MedKoo Cat#: 526957 | Name: GS-0938

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GS-0938, also known as PSI-352938; PSI-938, is a HCV NS5B inhibitor potentially for the treatment of HCV infection. PSI-352938 exhibits a novel mechanism of resistance requiring multiple mutations within replicon RNA.

Chemical Structure

GS-0938

CAS#1231747-17-3

Theoretical Analysis

MedKoo Cat#: 526957

Name: GS-0938

CAS#: 1231747-17-3

Chemical Formula: C16H23FN5O6P

Exact Mass: 431.1370

Molecular Weight: 431.36

Elemental Analysis: C, 44.55; H, 5.37; F, 4.40; N, 16.24; O, 22.25; P, 7.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

GS-0938; GS 0938; GS0938; PSI-352938; PSI-938; PSI352938; PSI938.

IUPAC/Chemical Name

(4aR,6R,7R,7aR)-6-(2-amino-6-ethoxy-9H-purin-9-yl)-7-fluoro-2-isopropoxy-7-methyltetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine 2-oxide

InChi Key

PVRFQJIRERYGTQ-UYISCHNFSA-N

InChi Code

InChI=1S/C16H23FN5O6P/c1-5-24-13-10-12(20-15(18)21-13)22(7-19-10)14-16(4,17)11-9(26-14)6-25-29(23,28-11)27-8(2)3/h7-9,11,14H,5-6H2,1-4H3,(H2,18,20,21)/t9-,11-,14-,16-,29?/m1/s1

SMILES Code

C[C@]1(F)[C@H](N2C=NC3=C(OCC)N=C(N)N=C23)O[C@@]4([H])[C@@]1([H])OP(OC4)(OC(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 431.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015 Jun;61(6):1793-7. doi: 10.1002/hep.27814. PubMed PMID: 25846014. 2: Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 - 2013: hepatitis C virus infection. Expert Opin Investig Drugs. 2015 Feb;24(2):239-51. doi: 10.1517/13543784.2015.982274. PubMed PMID: 25384989. 3: Lam AM, Edwards TE, Mosley RT, Murakami E, Bansal S, Lugo C, Bao H, Otto MJ, Sofia MJ, Furman PA. Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance. Antimicrob Agents Chemother. 2014 Nov;58(11):6861-9. doi: 10.1128/AAC.03847-14. PubMed PMID: 25182647; PubMed Central PMCID: PMC4249362. 4: De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. PubMed PMID: 24735613. 5: Guedj J, Pang PS, Denning J, Rodriguez-Torres M, Lawitz E, Symonds W, Perelson AS. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther. 2014;19(2):211-20. doi: 10.3851/IMP2733. PubMed PMID: 24464551. 6: Lawitz EJ, Rodriguez-Torres M, Denning J, Mathias A, Mo H, Gao B, Cornpropst MT, Berrey MM, Symonds WT. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). J Viral Hepat. 2013 Oct;20(10):699-707. doi: 10.1111/jvh.12091. PubMed PMID: 24010644. 7: Du J, Bao D, Chun BK, Jiang Y, Reddy PG, Zhang HR, Ross BS, Bansal S, Bao H, Espiritu C, Lam AM, Murakami E, Niu C, Micolochick Steuer HM, Furman PA, Otto MJ, Sofia MJ. β-D-2'-α-F-2'-β-C-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5924-9. doi: 10.1016/j.bmcl.2012.07.066. PubMed PMID: 22892115. 8: De Clercq E. Highlights in antiviral drug research: antivirals at the horizon. Med Res Rev. 2013 Nov;33(6):1215-48. doi: 10.1002/med.21256. Review. PubMed PMID: 22553111. 9: Niu C, Tolstykh T, Bao H, Park Y, Babusis D, Lam AM, Bansal S, Du J, Chang W, Reddy PG, Zhang HR, Woolley J, Wang LQ, Chao PB, Ray AS, Otto MJ, Sofia MJ, Furman PA, Murakami E. Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Antimicrob Agents Chemother. 2012 Jul;56(7):3767-75. doi: 10.1128/AAC.00530-12. PubMed PMID: 22526308; PubMed Central PMCID: PMC3393470. 10: Chun BK, Du J, Zhang HR, Chang W, Ross BS, Jiang Y, Bao D, Espiritu CL, Keilman M, Steuer HM, Furman PA, Sofia MJ. Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938. Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):886-96. doi: 10.1080/15257770.2011.614308. PubMed PMID: 22060553. 11: Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Zennou V, Otto MJ, Furman PA. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol. 2011 Dec;85(23):12334-42. doi: 10.1128/JVI.05639-11. PubMed PMID: 21957306; PubMed Central PMCID: PMC3209386. 12: Reddy PG, Chun BK, Zhang HR, Rachakonda S, Ross BS, Sofia MJ. Stereoselective synthesis of PSI-352938: a β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyl-3',5'-cyclic phosphate nucleotide prodrug for the treatment of HCV. J Org Chem. 2011 May 20;76(10):3782-90. doi: 10.1021/jo200060f. PubMed PMID: 21469736. 13: Lam AM, Espiritu C, Murakami E, Zennou V, Bansal S, Micolochick Steuer HM, Niu C, Keilman M, Bao H, Bourne N, Veselenak RL, Reddy PG, Chang W, Du J, Nagarathnam D, Sofia MJ, Otto MJ, Furman PA. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother. 2011 Jun;55(6):2566-75. doi: 10.1128/AAC.00032-11. PubMed PMID: 21444700; PubMed Central PMCID: PMC3101412. 14: Reddy PG, Bao D, Chang W, Chun BK, Du J, Nagarathnam D, Rachakonda S, Ross BS, Zhang HR, Bansal S, Espiritu CL, Keilman M, Lam AM, Niu C, Steuer HM, Furman PA, Otto MJ, Sofia MJ. 2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7376-80. doi: 10.1016/j.bmcl.2010.10.035. PubMed PMID: 21050754.